Page 5 - Response Authority News Today

The European Commissions Health Emergency Preparedness and Response Authority (HERA), working with the Belgian EU Presidency, launched on 24 April the Critical Medicines Alliance. The Alliance brings together national authorities, industry, healthcare organisations, civil society representatives, the Commission and EU agencies to identify the best measures to address and avoid shortages of critical medicines.

EU and Türkiye deepen cooperation on green and digital transition - Commission launches the Critical Medicines Alliance to help prevent and address shortages of critical medicines - Commission disburses additional €1.5 billion in bridge financing to Ukraine - Commission launches first investigation under EU International Procurement Instrument - Commission issues recommendations to better protect children from violence - European Commission issues €8 billion in its 4th syndicated transactio...

One in five samples of retail milk in the U.S. have tested positive for viral fragments.

The new advisors will supply expertise in immunology, pathology, inflammatory processes and in MetrioPharms lead indication Duchenne muscular dys...

Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results ...

Focus on new treatments as Covid vaccine sales fell from $18.4 billion in 2022 to $6.8 billion last year

(Reuters) -Moderna on Thursday reported a surprise fourth-quarter profit, helped by cost cutting and some deferred payments, and the vaccine maker set out a commercial roadmap for its experimental respiratory syncytial virus (RSV) shot. Moderna posted a profit of $217 million, or 55 cents a share, for the quarter. Moderna Chief Financial Officer James Mock in an interview said the company beat its own forecast because of unexpected deferred revenue of $600 million and cost savings of around $3...

Posts fourth quarter revenues of $2.8 billion, GAAP net income of $217 million and GAAP diluted EPS of $0.55Reports full-year revenues of $6.8 billion, GAAP net loss of $(4.7) billion and GAAP diluted EPS of $(12.33); loss primarily driven by mostly non-cash charges of $3.7 billion related to resizing and a tax valu...

Moderna reports Q4 2023 revenues of $2.81 billion from Spikevax (COVID-19 vaccine), exceeding expectations.

Negotiations of the multilateral pandemic agreement are on the wrong track. At stake is our chance of preventing the next global infectious crisis from turning into another catastrophe